Scott White - Hyperfine Chief Officer
HYPR Stock | USD 0.99 0.02 2.06% |
Insider
Scott White is Chief Officer of Hyperfine
Age | 50 |
Address | 351 New Whitfield Street, Guilford, CT, United States, 06437 |
Phone | 866 796 6767 |
Web | https://hyperfine.io |
Hyperfine Management Efficiency
The company has return on total asset (ROA) of (0.3196) % which means that it has lost $0.3196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5393) %, meaning that it created substantial loss on money invested by shareholders. Hyperfine's management efficiency ratios could be used to measure how well Hyperfine manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/27/2025, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Hyperfine's Total Assets are relatively stable compared to the past year. As of 02/27/2025, Net Tangible Assets is likely to grow to about 149.4 M, while Non Currrent Assets Other are likely to drop slightly above 1.8 M.Similar Executives
Showing other executives | INSIDER Age | ||
Brian MD | PAVmed Inc | 60 | |
BA Chemistry | Orthofix Medical | 63 | |
Chi Nguyen | Neuropace | 47 | |
Martha Morrell | Neuropace | 67 | |
Christopher Holland | Electromed | 55 | |
Agnes Lee | Inogen Inc | N/A | |
Nabil Shabshab | Inogen Inc | 59 | |
Matthew Pigeon | Inogen Inc | N/A | |
John Glenn | Iradimed Co | 63 | |
Mark Quick | Orthofix Medical | N/A | |
Mark Saxton | Neuropace | 59 | |
George Parr | Inogen Inc | 53 | |
McAlister Marshall | Integer Holdings Corp | 51 | |
Adrian Miller | PAVmed Inc | N/A | |
John McKune | Pulmonx Corp | 49 | |
Ehab Esmail | Orthofix Medical | 53 | |
Kristin Caltrider | Inogen Inc | 56 | |
Michael Hutchinson | LivaNova PLC | 54 | |
Alex Shvartsburg | LivaNova PLC | 54 | |
Bart Bracy | Anika Therapeutics | N/A | |
Charles III | Anika Therapeutics | N/A |
Management Performance
Return On Equity | -0.54 | ||||
Return On Asset | -0.32 |
Hyperfine Leadership Team
Elected by the shareholders, the Hyperfine's board of directors comprises two types of representatives: Hyperfine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hyperfine. The board's role is to monitor Hyperfine's management team and ensure that shareholders' interests are well served. Hyperfine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hyperfine's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott White, Chief Officer | ||
Neela Paykel, Gen Officer | ||
Alok Gupta, Chief Officer | ||
Thomas Teisseyre, Chief Officer | ||
Dave Castiglioni, Chief Officer | ||
Maria Sainz, President CEO | ||
Brett Hale, CFO, Officer | ||
Edmond MD, Chief Officer | ||
Mark Hughes, VP Operations | ||
Jonathan Rothberg, Founder Chairman | ||
Khan MD, Chief Officer | ||
Kyla JD, Chief Officer | ||
MD FACR, Vice Affairs | ||
Tom Teisseyre, Chief Officer |
Hyperfine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hyperfine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.54 | ||||
Return On Asset | -0.32 | ||||
Operating Margin | (3.01) % | ||||
Current Valuation | 29.72 M | ||||
Shares Outstanding | 62.4 M | ||||
Shares Owned By Insiders | 8.75 % | ||||
Shares Owned By Institutions | 22.77 % | ||||
Number Of Shares Shorted | 1.34 M | ||||
Price To Book | 1.29 X | ||||
Price To Sales | 5.69 X |
Additional Tools for Hyperfine Stock Analysis
When running Hyperfine's price analysis, check to measure Hyperfine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hyperfine is operating at the current time. Most of Hyperfine's value examination focuses on studying past and present price action to predict the probability of Hyperfine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hyperfine's price. Additionally, you may evaluate how the addition of Hyperfine to your portfolios can decrease your overall portfolio volatility.